瓦里安将以164亿美元的全现金交易与西门子医疗合并 | Varian

{ "pageType": "news-article", "title": "瓦里安将以164亿美元的全现金交易与西门子医疗合并", "articleDate": "2 de August de 2020", "introText": "", "category": "Corporate and Financial Releases" }

瓦里安将以164亿美元的全现金交易与西门子医疗合并

  • 强强联合产品线高度互补,将增强临床医生和癌症患者战胜癌症的力量
  • 建立覆盖端到端的肿瘤解决方案的全集成平台,将确保整个癌症治疗的连续性——从筛查和诊断,治疗护理,到疗后生存
  • 创建领先的数字医疗保健平台,整合真实世界的临床证据和人工智能技术,合并后的公司将以软件、数据和技术带来颠覆性的癌症治疗解决方案
  • 瓦里安股东将获得每股177.50美元现金,代表42%的溢价

加州帕洛阿托, 2020年8月2日 - 瓦里安(NYSE: VAR)今天宣布,已与西门子医疗(Siemens Healthineers AG, Frankfurt: SHL) 就合并达成最终协议,在完全摊薄的基础上全现金交易价值164亿美元。根据经瓦里安董事会一致批准的协议条款,西门子医疗将以每股177.50美元现金收购瓦里安的所有流通股份,与截至2020年7月31日瓦里安普通股30天成交量加权平均收盘价相比溢价约42%,与2020年7月31日交易公告前的最后一个交易日普通股收盘价相比溢价约24%。

这一强强联合将创建一个多学科的全球医疗领导者,拥有业内最全面的癌症治疗产品组合。合并后的公司将提供一个覆盖端到端的肿瘤解决方案的全集成平台,以确保癌症护理的整个连续性:从筛查和诊断,治疗护理,到疗后生存。通过将两家公司高度互补的诊断工具、影像、放射治疗和人工智能能力结合在一起,瓦里安和西门子医疗将引领肿瘤治疗的数字化转型,实现更高效的诊断、更高质的治疗、更广泛的可及和更个性化的精确癌症治疗,将提升全球数百万患者的治疗结果。

瓦里安全球总裁兼首席执行官魏思韬(Dow Wilson)表示:“今天的宣布标志着我们公司历史上的一个重要里程碑,瓦里安董事会坚信这是瓦里安正确的前进道路;我们与西门子医疗的合并除了为我们的股东带来直接、极有价值的回报之外,这也将让我们加速实现创造一个无惧癌症的世界这一变革性愿景。西门子医疗在检测和诊断方面的创新领导地位将使我们参与到抗癌的第一战线,为临床医生和患者提供服务。我们将全力以赴,致力于变革医疗服务以服务全世界更多的患者。”

魏思韬表示:“瓦里安不懈创新、秉承以患者为中心的公司文化,这使我们成为放射治疗和多学科癌症质量的标志性领导者,我们拥有值得信赖的全球品牌,赢得了客户的高度信赖。西门子医疗重视我们富有才华和敬业精神的员工,并认可瓦里安品牌的实力、我们的尖端产品组合以及我们缔结的联系。我们很高兴能与西门子联合,共同将我们领先的客户服务进一步扩展,惠及全球更多的患者。和西门子医疗一起,我们将可以加速实现我们的愿景,有意义地提高我们对患者的影响,同时并为我们的员工提供更多机会,加入一个更大规模、更多元化的组织。”

西门子医疗全球首席执行官Bernd Montag博士表示:“两家业界领先公司的强强联合,使我们一步实现了两次飞跃:一方面推动公司抗癌业务的飞跃,另一方面提升公司在医疗健康行业的整体影响力。在这样特殊的历史节点上做出这个决定,意味着我们对公司的发展满怀信心,致力于成为更强大的合作伙伴,同时为社会提供更有价值和更高效的医疗健康服务。与瓦里安杰出而充满激情的员工一起,我们将比以往更加勇往直前,共同塑造医疗行业的未来。”

交易预计将在2021年上半年完成,仍须经瓦里安股东及监管部门的批准,并满足其他惯例成交条件。

瓦里安已经建立了强大的品牌认知度,预期在交易完成后,将继续以瓦里安品牌在西门子医疗内作为一家独立公司运营。

 

2020财年第三季度财务业绩
在今天发布的另一份新闻稿中,瓦里安宣布了其2020财年第三季度的财务业绩。

顾问
高盛公司(Goldman Sachs&Co.LLC)是瓦里安的独家财务顾问,Wachtell、Lipton、Rosen&Katz担任法律顾问。

 

关于瓦里安

瓦里安以创造一个无惧癌症的世界为愿景。70多年来,我们研发、引领和提供创新的癌症治疗技术和解决方案,帮助为全球临床合作伙伴每年为数百万患者提供治疗。我们以人工智能、机器学习和数据分析等先进技术,打造智能癌症治疗方式,改进癌症治疗的方式,扩大癌症治疗的可及。我们10000名员工遍及70个国家,始终以患者和临床合作伙伴为工作核心,不断激发对抗癌症的崭新胜利。因为,对于世界各地的癌症患者来说,他们的抗癌之路就是我们的抗癌之战。

 

Additional Information About the Merger and Where to Find It
This communication relates to the proposed transaction involving Varian. This communication is not intended to and does not constitute an offer to sell or the solicitation of an offer to subscribe for or buy or an invitation to purchase or subscribe for any securities or the solicitation of any vote or approval in any jurisdiction, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in contravention of applicable law. In connection with the proposed transaction, Varian will file relevant materials with the U.S. Securities and Exchange Commission (the "SEC"), including Varian's proxy statement on Schedule 14A (the "Proxy Statement"). This communication is not a substitute for the Proxy Statement or any other document that Varian may file with the SEC or send to its stockholders in connection with the proposed transaction. BEFORE MAKING ANY VOTING DECISION, STOCKHOLDERS OF VARIAN ARE URGED TO READ ALL RELEVANT DOCUMENTS FILED OR TO BE FILED WITH THE SEC, INCLUDING THE PROXY STATEMENT, WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION. Investors and security holders will be able to obtain the documents (when available) free of charge at the SEC's website, www.sec.gov, and Varian's website, www.varian.com. In addition, the documents (when available) may be obtained free of charge by directing a request to Investor Relations by email at investors@varian.com or by calling (650) 424-5631.

Participants in the Solicitation
Varian and its directors and executive officers may be deemed to be participants in the solicitation of proxies from the holders of Varian's common stock in respect of the proposed transaction. Information about the directors and executive officers of Varian is set forth in the definitive proxy statement for Varian's 2020 Annual Meeting of Stockholders, which was filed with the SEC on December 20, 2019, or its Annual Report on Form 10-K for the year ended September 27, 2019, and in other documents filed by Varian with the SEC. Other information regarding the participants in the proxy solicitation and a description of their direct and indirect interests, by security holdings or otherwise, will be contained in the Proxy Statement and other relevant materials to be filed with the SEC in respect of the proposed transaction when they become available.

Forward-Looking Statements
Except for historical information, this communication contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements concerning Varian's future orders and the anticipated impact of the COVID-19 pandemic on Varian's business; and any statements using the terms "could," "believe," "expect," "promising," "outlook," "should," "well-positioned," "will" or similar statements are forward-looking statements that involve risks and uncertainties that could cause Varian's actual results to differ materially from those anticipated. Such risks and uncertainties include: (1) the future impact of the COVID-19 pandemic on Varian's business, including but not limited to, the impact on its workforce, operations, supply chain, demand for products and services, and Varian's financial results and condition; (2) Varian's ability to successfully manage the challenges associated with the COVID-19 pandemic; (3) Varian's ability to achieve expected synergies from acquisitions; (3) risks associated with integrating recent acquisitions; (4) global economic conditions and changes to trends for cancer treatment regionally; (5) currency exchange rates and tax rates; (5) the impact of the Tax Cuts and Jobs Act; (6) the impact of the Affordable Health Care for America Act (including excise taxes on medical devices) and any further healthcare reforms (including changes to Medicare and Medicaid), and/or changes in third-party reimbursement levels; (7) recent and potential future tariffs or a global trade war; (8) demand for and delays in delivery of Varian's products; (9) Varian's ability to develop, commercialize and deploy new products; (10) Varian's ability to meet Food and Drug Administration (FDA) and other regulatory requirements, regulations or procedures; (11) changes in regulatory environments; (12) risks associated with Varian providing financing for the construction and start-up operations of particle therapy centers, challenges associated with commercializing Varian's Proton Solutions business; (13) challenges to public tender awards and the loss of such awards or other orders; (14) the effect of adverse publicity; (15) Varian's reliance on sole or limited-source suppliers; (16) Varian's ability to maintain or increase margins; (17) the impact of competitive products and pricing; (18) the potential loss of key distributors or key personnel; (19) challenges related to entering into new business lines; (20) the occurrence of any event, change or other circumstances that could give rise to the termination of the agreement; (21) the failure to obtain the approval of Varian's stockholders, the failure to obtain certain required regulatory approvals or the failure to satisfy any of the other closing conditions to the completion of the transaction, (22) risks related to disruption of management's attention from Varian's ongoing business operations due to the transaction; (23) the effect of the announcement of the transaction on the ability of Varian to retain and hire key personnel and maintain relationships with its customers, suppliers and others with whom it does business, or on its operating results and business generally; (24) the ability to meet expectations regarding the timing and completion of the transaction; and (25) the other risks listed from time to time in Varian's filings with the SEC. For additional information concerning factors that could cause actual results and events to differ materially from those projected herein, please refer to Varian's Annual Report on Form 10-K for the year ended September 27, 2019 and subsequent Current Reports on Form 8-K and Quarterly Reports on Form 10-Q filed with the SEC. Varian assumes no obligation to update or revise the forward-looking statements in this communication because of new information, future events, or otherwise.

 

投资关系部联络方式
Anshul Maheshwari
+1 (650) 424-5631
investors@varian.com

媒体联系人
Eric Brielmann / Kaitlin Kikalo / Sophie Throsby
Joele Frank, Wilkinson Brimmer Katcher
+ 1 (415) 869-3950 / +1 (212) 355-4449